Share Name Share Symbol Market Type Share ISIN Share Description
Syncona LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.90p -1.72% 166.00p 166.50p 167.30p 168.40p 166.40p 168.40p 186,014 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 14.6 5.9 1.3 129.7 1,093.42

Syncona Share Discussion Threads

Showing 18276 to 18298 of 18300 messages
Chat Pages: 732  731  730  729  728  727  726  725  724  723  722  721  Older
DateSubjectAuthorDiscuss
05/8/2017
08:38
I think I will buy more of these next week. I also like the fact they are giving us some additional shares. Whilst it's difficult to put a vale on the potential, if a few more companies get to full commercialisation then, as per Blue Earth, we could see quick uptake and associated increases in revenue.
audigger
05/8/2017
07:46
hxxp://www.blueearthdiagnostics.com/blue-earth-diagnostics-appoints-m2i-manufacture-distribute-axumin-ireland/ first product rolling out fast across Europe
luxaeterna1
01/8/2017
07:43
Bought 100k yesterday as a long term lockaway.The future looks bright for this company imo.
ltinvestor
10/7/2017
15:58
Cheers Alan, I'd like to think that Blue Earth will ramp up revenue significantly this year, now that our first product is legal in both EU and US.
luxaeterna1
10/7/2017
15:50
luxereterna1 - You can find the info if you click on the Financials tab at the top of this webpage, and scroll down a bit. It says:- Announcement Date: 06 Jul 2017 Final: 2.30p Record Date: 20/07/2017 Ex divi date: 21/07/2017 Payable: 23/08/2017
alan@bj
10/7/2017
13:32
Is the dividend payable in August @2.3p? I couldn't quite see that clarified anywhere
luxaeterna1
07/7/2017
04:01
Well worth listening to the results presentation webcast: httPS://www.synconaltd.com/results-centre/
rambutan2
06/7/2017
08:23
Impending results perhaps...? I find the narrative excessively verbose!
audigger
05/7/2017
08:07
In auction this morning- no RNS so what is the word on the street.....?? Interested to see what's up. DL
davidlloyd
30/6/2017
18:48
New funding round and write up for NightstaRx: https://uk.advfn.com/stock-market/london/syncona-SYNC/share-news/Syncona-Limited-NightstaRx-completes-US-45m-Series/75125958 And May factsheet: hTTp://content.prnewswire.com/documents/PRNUK-3006170935-131F_Syncona_Factsheet_May_2017_CC.pdf
rambutan2
31/5/2017
19:36
Well I'm on board. Lots to like about the business model, focus on UK innovation and charitable aspects of returning a proportion of NAV. I also like the fact the compared to investing in a single company, the risk is more balanced across a portfolio of opportunities. Having lost some good money on life science start-ups that ran out of cash and/or had bad trials results, balancing risk is appealing. I guess the tricky bit is how to judge the potential upside in share price with diverse portfolio where one has to expect winners and losers. It matters not so long as the trend is upwards!
audigger
23/5/2017
08:36
Blue Earth receives above mentioned approval for Europe: SynconaBlue Earth Diagnostics achieves EMA approval on Axumin Syncona Ltd ("Syncona"), a leading healthcare company focused on investing in and building global leaders in life science, is pleased to note that its portfolio company Blue Earth Diagnostics has received confirmation of approval of its product AxuminT (fluciclovine (18F)) ("Axumin") by the European Commission. This follows the announcement on 24 March 2017 that the Committee for Medicinal Products for Human Use had made a positive recommendation for Axumin to be granted marketing authorisation. The approval means that Axumin is now authorised to be sold in all European Union member states as well as Iceland, Liechtenstein and Norway. Axumin will initially be commercially available in Norway, with roll-out to additional countries planned in 2018. Syncona holds a 90 per cent interest in the share capital of Blue Earth Diagnostics.
rambutan2
25/3/2017
00:49
Quite exciting: Blue Earth Diagnostics achieves positive CHMP opinion on Axumin 24 March 2017 * Axumin receives positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, a key milestone in securing European approval * Positive progress in the USA market following the commencement of sales of Axumin in August 2016 * Syncona's investment in Blue Earth Diagnostics written up from GBP83.5 million to GBP109.01 million adding GBP25.5 million (3.9p per share) to Syncona Ltd's NAV Syncona Ltd ("Syncona"), is pleased to note the announcement by its portfolio company Blue Earth Diagnostics Limited ("Blue Earth") that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending that Axumin be granted marketing authorisation in the European Union. Syncona holds a 90 per cent interest in the share capital of Blue Earth. The recommendation is for Axumin (fluciclovine 18F) use in Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. This is an area of significant unmet need. A CHMP positive opinion is a key step in achieving approval to sell Axumin in the European Union. The opinion on Axumin will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision is expected in the coming months and would be applicable to all European Union member states as well as in Iceland, Liechtenstein and Norway. Axumin was approved by the Food and Drug Administration (FDA) in the United States of America in May 2016, and sales commenced in August 2016.Since this time the business has continued to make good strategic and commercial progress in the region. The positive opinion of the CHMP, coupled with good progress in the USA, has resulted in Syncona's investment in Blue Earth being written up to GBP109.01 million, a GBP25.5 million (3.9p per share) uplift to the last published valuation of GBP83.5 million. Syncona Investment Management partner and Blue Earth director Iraj Ali, said, "In the three years since formation Blue Earth has successfully delivered to the US market a product with the potential to transform how patients with recurrent prostate cancer are treated. It is now a significant step closer to doing the same in Europe, which is testament to the efficacy of the product, hard work of the team and the strength of Syncona's long term partnership model." Blue Earth chief executive, Jonathan Allis, said, "The CHMP's positive recommendation for Axumin is a major advance for Blue Earth. We now look forward to working with our commercial manufacturing and distribution associates to be ready to make Axumin widely available to doctors and their patients across Europe."
rambutan2
06/3/2017
12:56
Good to see that along with a Capital Mkts Day they've launched a proper website today, as befits a ftse 250 investment company. Comprehensive presentation: htTP://www.synconaltd.com/wp-content/uploads/2017/03/Syncona-Capital-Markets-Day-March-2017.pdf
rambutan2
03/3/2017
01:59
Promoted into ftse 250, with effect from mon 20th. http://www.investegate.co.uk/ftse/rns/ftse-uk-index-series/201703011739112850Y/
rambutan2
10/2/2017
13:29
Is 9% of nav: BURLINGTON, Mass. and OXFORD, England February 7, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, and Siemens’ PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., announce the increasing number of radiopharmacies offering Blue Earth Diagnostics’ Axumin (fluciclovine F 18) PET imaging agent through PETNET’s national network. hTTp://www.blueearthdiagnostics.com/axumin-fluciclovine-f-18-injection-pet-imaging-agent-suspected-recurrent-prostate-cancer/
rambutan2
29/1/2017
03:45
First fact sheet post enlargement and remit change: htTP://content.prnewswire.com/documents/PRNUK-2701171238-5B58_Syncona_Factsheet_December_2016_CC.pdf
rambutan2
29/1/2017
03:45
hTTp://synconaltd.com//wp-content/uploads/BACIT-Limited-Prospectus-28-November-2016.pdf Historical info on Syncona pre BACIT merger: httPS://wellcome.ac.uk/press-release/wellcome-trust-launch-%C2%A3200-million-investment-business-healthcare-and-life-sciences hTTps://wellcome.ac.uk/press-release/launch-syncona-partners httPS://www.bloomberg.com/news/articles/2013-01-03/wellcome-trust-starts-326-million-health-investment-arm htTps://www.cbinsights.com/investor/syncona-partners httPS://www.crunchbase.com/organization/syncona-partners-llp#/entity
rambutan2
29/1/2017
03:43
hTTp://synconaltd.com/ httPs://wellcome.ac.uk/news/syncona-join-forces-leading-investment-trust hTTp://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-11-07-cancer-research-uk-joins-forces-with-wellcome-trust-syncona-and-bacit-to-create-life-sciences htTP://www.telegraph.co.uk/business/2016/11/07/1bn-fund-to-reignite-uk-life-sciences-companies-with-long-term-f/ Bio investments: hTTp://www.blueearthdiagnostics.com/ httPS://www.nightstarx.com/ httP://www.autolus.com/ hTTp://www.freelinetx.com/ httPS://www.cambridge-epigenetix.com/ hTTp://achillestx.com/ hTtp://sixthelementcapital.com/index.php/portfolio (aka The Pioneer Fund)
rambutan2
30/12/2016
17:51
Use other thread
rambutan2
20/12/2016
15:28
Deja vu...... DL
davidlloyd
27/5/2014
10:48
New MYRN threads have been set up - see links below: hTTp://uk.advfn.com/cmn/fbb/thread.php3?id=32016165 hTTp://uk.advfn.com/cmn/fbb/thread.php3?id=31875170 For all those interested in following this stock perhaps you should migrate across. Thanks.
plunge
26/5/2014
23:40
busy today!!! RNS expected.?
maqsud
Chat Pages: 732  731  730  729  728  727  726  725  724  723  722  721  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170818 04:56:08